This is exemplified in the development of CDX-1401 which contains a DC receptor (DEC-205, CD205) specific monoclonal antibody to deliver the conjugated tumor antigen NY-ESO-1 in combination with TLR7/8 agonists (167), and is now in clinical trials combined with IDO1 inhibition (NCT02166905). Here, LY75 is linked to neoplasm.